http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
-
Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
-
Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021
-
Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea
-
Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea
-
Novavax (NVAX) Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
-
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
-
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
-
Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine
-
Novavax Announces Memorandum of Understanding to Produce COVID-19 Vaccine Made in Canada
-
Novavax to Present COVID-19 Vaccine Candidate Data at New York Academy of Science
-
Novavax (NVAX) Says COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
-
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
-
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
-
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine
-
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine
-
Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management
-
Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer
-
Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer
-
Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine
-
Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine
-
Novavax to Participate in Upcoming Conferences
-
Novavax (NVAX) Confirms Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in U.S. & Mexico
-
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
-
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
-
Novavax (NVAX) announces appointment of Rick Crowley to newly created position of EVP, COO
-
Biopharma Executive Rick Crowley Joins Novavax as Chief Operations Officer
-
Biopharma Executive Rick Crowley Joins Novavax as Chief Operations Officer
-
Novavax (NVAX) Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine
-
Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine
-
Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine
-
Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors
-
Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors
-
Novavax (NVAX) Announces COVID-19 Vaccine Clinical Development Progress
-
Novavax Announces COVID-19 Vaccine Clinical Development Progress
-
Novavax Announces COVID-19 Vaccine Clinical Development Progress
-
Novavax to Participate in Upcoming Conferences
-
Novavax to Participate in Upcoming Conferences
-
Novavax to Host Conference Call for Questions Related to Third Quarter Financial and Operating Results on November 10, 2020
-
Novavax to Host Conference Call for Questions Related to Third Quarter Financial and Operating Results on November 10, 2020
-
Novavax (NVAX) Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates
-
Novavax Reports Third Quarter 2020 Financial and Operational Results
-
Novavax Reports Third Quarter 2020 Financial and Operational Results
-
Novavax Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates
-
Novavax Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates
-
Novavax (NVAX) COVID-19 Vaccine Granted FDA Fast Track Designation
-
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
-
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
-
Novavax (NVAX) Confirms Commonwealth of Australia Announced Agreement in Principle for Acquisition of Novavax COVID-19 Vaccine
-
Novavax and Commonwealth of Australia Announce Agreement in Principle for Acquisition of Novavax COVID-19 Vaccine

